Patent · US Active

Morpholinopurine derivatives

US8309546B2 · kind B2 · utility

6Cited by

10References

16Claims

0Family size

Assignee

DAIICHI SANKYO COMPANY, LIMITED · JP

Inventors

Kiyoshi Nakayama · Tokyo, JP
Kazuyuki Sugita · Tokyo, JP
Masaki Setoguchi · Tokyo, JP
Yuichi Tominaga · Shinagawa, JP
Masanori Saitou · Tokyo, JP
Takashi Odagiri · Yokohama, JP

Key dates

Filing date	Nov 30, 2011
Grant date	Nov 13, 2012
Priority date	—
Expiry date	Nov 30, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

There is provided a novel compound that inhibits phosphatidylinositol 3-kinase (PI3K) and/or the mammalian target of rapamycin (mTOR) and exhibits anti-tumor activity. The present invention provides a compound represented by the following formula (1) having various substituents that inhibits PI3K and/or mTOR and exhibits anti-tumor activity:wherein R1, R2, R3, R4, Ra, Rb, Rc, and X each have the same meaning as defined in the specification.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.